Arcellx, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACLX research report →
Companyarcellx.com
Arcellx, Inc. , a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).
- CEO
- Rami Elghandour
- IPO
- 2022
- Employees
- 163
- HQ
- Redwood City, MD, US
Price Chart
Valuation
- Market Cap
- $6.73B
- P/E
- -28.30
- P/S
- 302.09
- P/B
- 16.10
- EV/EBITDA
- -34.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -64.81%
- Op Margin
- -1135.61%
- Net Margin
- -1027.25%
- ROE
- -55.42%
- ROIC
- -49.88%
Growth & Income
- Revenue
- $22.29M · -79.35%
- Net Income
- $-228,934,000 · -113.26%
- EPS
- $-4.07 · -103.50%
- Op Income
- $-253,083,000
- FCF YoY
- -119.38%
Performance & Tape
- 52W High
- $115.13
- 52W Low
- $50.85
- 50D MA
- $112.62
- 200D MA
- $84.15
- Beta
- 0.25
- Avg Volume
- 1.45M
Get TickerSpark's AI analysis on ACLX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 26 | Carroll Jill | other | 1,479,148 |
| Apr 28, 26 | Carroll Jill | sell | 11,459 |
| Apr 28, 26 | Carroll Jill | sell | 8,011 |
| Apr 28, 26 | Carroll Jill | sell | 9,174 |
| Apr 28, 26 | Behbahani Ali | other | 2,706 |
| Apr 28, 26 | Behbahani Ali | sell | 11,459 |
| Apr 28, 26 | Behbahani Ali | sell | 8,011 |
| Apr 28, 26 | Behbahani Ali | sell | 9,174 |
| Apr 28, 26 | Ware Olivia C | sell | 36,806 |
| Apr 28, 26 | Ware Olivia C | sell | 11,459 |
Our ACLX Coverage
We haven't published any research on ACLX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACLX Report →